Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies

Treatment of Graves' disease (GD) with the B-lymphocyte depleting agent rituximab in addition to standard methimazole-therapy prolongs remission. Paradoxically, it does not mediate a reduction in thyrotropin receptor antibody (TRAb) levels over that of methimazole monotherapy. Using a bioassay...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical immunology (Orlando, Fla.). - 1999. - 130(2009), 3 vom: 15. März, Seite 252-8
1. Verfasser:	El Fassi, Daniel (VerfasserIn)
Weitere Verfasser:	Banga, J Paul, Gilbert, Jacqueline A, Padoa, Carolyn, Hegedüs, Laszlo, Nielsen, Claus H
Format:	Online-Aufsatz
Sprache:	English
Veröffentlicht:	2009
Zugriff auf das übergeordnete Werk:	Clinical immunology (Orlando, Fla.)
Schlagworte:	Controlled Clinical Trial Journal Article Research Support, Non-U.S. Gov't Antibodies, Monoclonal Antibodies, Monoclonal, Murine-Derived Autoantibodies Immunoglobulins, Thyroid-Stimulating Immunologic Factors Rituximab 4F4X42SYQ6 mehr... Cyclic AMP E0399OZS9N